BVF PARTNERS L P/IL
Transactions
50
Companies
71
Filings
7
CIK
0001055947
Recent Transactions
- Sale
Common Stock, $0.0001 par value
2026-06-26$106.50/sh−837,914→ 1,960,881 total - Sale
Common Stock, $0.0001 par value
2026-06-26$106.50/sh−627,597→ 1,592,261 total - Sale
Common Stock, $0.0001 par value
2026-06-26$106.50/sh−113,289→ 240,123 total - Sale
Common Stock, $0.0001 par value
2026-06-26$106.50/sh−51,858→ 78,787 total - Award
- Award
- Award
- ConversionXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2026-05-14$4.03/sh+2,313,000→ 3,635,758 total - ConversionXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2026-05-14$4.03/sh+1,506,000→ 2,773,545 total - ConversionXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2026-05-14$4.03/sh+412,000→ 412,000 total - ConversionXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2026-05-14$4.03/sh+772,000→ 772,000 total - Conversion
- Conversion
- Conversion
- Conversion
- Sale
Class A Ordinary Shares, $0.0001 par value
2026-03-31$16.79/sh−1,932,354→ 8,302,735 total - Sale
Class A Ordinary Shares, $0.0001 par value
2026-03-31$16.79/sh−1,569,116→ 6,599,722 total - Sale
Class A Ordinary Shares, $0.0001 par value
2026-03-31$16.79/sh−248,530→ 1,039,238 total - Disposition from Tender
- Disposition from Tender
- Disposition from Tender
- Disposition from Tender
- Disposition from Tender
- Disposition from Tender
- Exercise of In-Money
- Sale
- Exercise of In-Money
- Exercise of In-Money
- Exercise of In-Money
- Exercise of In-Money
- Exercise of In-Money
- Sale
- Sale
- Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604→ 2,798,795 total - Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780→ 353,412 total - Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783→ 2,219,858 total - Award
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total - Other
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total - Other
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total - Other
- Award
- Award
- SaleXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2025-05-16$27.10/sh−127,407→ 1,322,758 total - SaleXOMA Royalty Corp$XOMA
Common Stock, $0.0075 par value per share
2025-05-16$27.10/sh−265,316→ 1,267,545 total - Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
Companies
71- $FDMT
4D Molecular Therapeutics, Inc.
See Explanation of Responses
ABBOTT BIOTHERAPEUTICS CORP
10% Owner
ADOLOR CORP
10% Owner
AEOLUS PHARMACEUTICALS, INC.
10% Owner, Indirect Beneficial Owner
AEROGEN INC
10% Owner, Indirect Beneficial Owner
ALPINE IMMUNE SCIENCES, INC.
10% Owner
AMAG PHARMACEUTICALS, INC.
10% Owner, Indirect Beneficial Owner
ARENA PHARMACEUTICALS INC
10% Owner, Indirect Beneficial Owner
ARQULE INC
10% Owner
ARRAY BIOPHARMA INC
10% Owner
AVIGEN INC \DE
10% Owner
Allakos Inc.
10% Owner
Astex Pharmaceuticals, Inc
10% Owner
- $BCRX
BIOCRYST PHARMACEUTICALS INC
10% Owner, Indirect Beneficial Owner
CONCERT PHARMACEUTICALS, INC.
10% Owner
CORVAS INTERNATIONAL INC
10% Owner
- $CBIO
CRESCENT BIOPHARMA, INC.
10% Owner
CTI BIOPHARMA CORP
10% Owner
- $CRIS
CURIS INC
10% Owner, Indirect Beneficial Owners
- $CYTK
CYTOKINETICS INC
10% Owner
Calithera Biosciences, Inc.
10% Owner
- $CAPS
Capstone Holding Corp.
10% Owner
Cascadian Therapeutics, Inc.
10% Owner
Celera CORP
10% Owner
ChemoCentryx, Inc.
10% Owner
- $CGEM
Cullinan Therapeutics, Inc.
10% Owner
CytoCore, Inc.
10% Owner, Indirect Beneficial Owner
- $CTMX
CytomX Therapeutics, Inc.
10% Owner
- $DVAX
DYNAVAX TECHNOLOGIES CORP
10% Owner, Indirect Beneficial Owner
EPIRUS Biopharmaceuticals, Inc.
10% Owner
- $EPIX
ESSA Pharma Inc.
10% Owner
- $ELDN
Eledon Pharmaceuticals, Inc.
10% Owner
FIVE PRIME THERAPEUTICS, INC.
10% Owner
GENAERA CORP
10% Owner
- $GYRE
GYRE THERAPEUTICS, INC.
10% Owner
ICAGEN INC
10% Owner
- $IDYA
IDEAYA Biosciences, Inc.
10% Owner
IMMUNE DESIGN CORP.
10% Owner
- $IMUX
IMMUNIC, INC.
Director, See Explanation of Responses
INFINITY PHARMACEUTICALS, INC.
10% Owner
INHIBITEX, INC.
10% Owner, Indirect Beneficial Owners
KENT INTERNATIONAL HOLDINGS INC
See Explanation of Responses
- $KYMR
Kymera Therapeutics, Inc.
Director, See Remarks and Footnotes
- $LGND
LIGAND PHARMACEUTICALS INC
10% Owner, Indirect Beneficial Owner
- $MNOV
MEDICINOVA INC
10% Owner
- $MRUS
Merus N.V.
10% Owner
- $MLTX
MoonLake Immunotherapeutics
Director, 10% Owner
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/
10% Owner
- $NBIX
NEUROCRINE BIOSCIENCES INC
10% Owner, Indirect Beneficial Owner
NEUROGEN CORP
10% Owner, Indirect Beneficial Owner
- $OLMA
Olema Pharmaceuticals, Inc.
Director, See Explanation of Responses
- $PTN
PALATIN TECHNOLOGIES INC
10% Owner
- $PVLA
PALVELLA THERAPEUTICS, INC.
10% Owner
PHARMACOPEIA INC
10% Owner, Indirect Beneficial Owners
POINT Biopharma Global Inc.
10% Owner
Principia Biopharma Inc.
10% Owner
- $RGEN
REPLIGEN CORP
10% Owner, Group Member
REPROS THERAPEUTICS INC.
10% Owner, Indirect Beneficial Owner
- $RIGL
RIGEL PHARMACEUTICALS INC
10% Owner
Rain Oncology Inc.
Director, See Remarks
Regulus Therapeutics Inc.
10% Owner
- $RPTX
Repare Therapeutics Inc.
10% Owner
SGX PHARMACEUTICALS, INC.
10% Owner, Indirect Beneficial Owner
- $GPCR
Structure Therapeutics Inc.
10% Owner
- $SNDX
Syndax Pharmaceuticals Inc
10% Owner
Third Harmonic Bio, Inc.
10% Owner
Tobira Therapeutics, Inc.
See Explanation of Responses
- $VSTM
Verastem, Inc.
10% Owner
- $XOMA
XOMA Royalty Corp
10% Owner
- $XENE
Xenon Pharmaceuticals Inc.
10% Owner
- $ENGN
enGene Therapeutics Inc.
10% Owner
Recent Filings
7Address
44 MONTGOMERY STREET 40TH FLOOR
SAN FRANCISCO, CA, 94104